In vivo modeling of human liver for pharmacological study using humanized mouse

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 11, 2009, Pages 1435-1446

  Yoshizato, Katsutoshi ^a,b   Tateno, Chise ^a  

^a PhoenixBio USA Corporation   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Human hepatocytes; Humanized mouse; Immunodeficient mouse; In vivo drug metabolism

Indexed keywords

3 METHYLCHOLANTHRENE; 4'2 HYDROXYDEBRISOQUIN; ABC TRANSPORTER; ACYLTRANSFERASE; ANTILIPEMIC AGENT; CARBOXYLIC ACID DERIVATIVE; CEFMETAZOLE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEBRISOQUINE; DRUG METABOLITE; FIBRIC ACID DERIVATIVE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN 3; ORGANIC ANION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 1; QUINIDINE; RIFAMPICIN; SULFOTRANSFERASE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

CELL POPULATION; CELL REGENERATION; CHIMERA; CONGENIC STRAIN; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TRANSFORMATION; DRUG TRANSPORT; ENZYME SPECIFICITY; HEPATITIS B; HEPATITIS C; HEPATITIS VIRUS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER; LIVER CELL; LIVER PARENCHYMA; METABOLIC DISORDER; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SCID MOUSE; STELLATE CELL; TRANSGENIC MOUSE; VIREMIA;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; GENETIC VECTORS; HEPATOCYTES; HUMANS; LIVER; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTANT CHIMERIC PROTEINS; PHARMACOLOGY; PHENOTYPE; SPECIES SPECIFICITY; VIRUSES;

EID: 70449090414     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903216664     Document Type: Review

References (50)

1. Zarnegar R, DeFrances MC, Michalopoulos GK. Hepatocyte growth factor. In: Arias IM, chief editor, The Liver. Raven Press, New York; 1994. p. 1047-1057
2. Tsanev R. Cell cycle and liver function. In: Reiner J, Holzer H, editors, Results and Problems in Cell Differentiation. Springer-Verlag, Berlin; 1975. p. 197-248
3. Stahl WR. Organ weights in primates and other mammals. Science 1965;150:1039-1042
4. Thiel V, Gavaler DH, Kam JS, et al. Rapid growth of an intact human liver transplanted into a recipient larger than the donor. Gastroenterology 1987;93:1414-1419
5. Heckel JL, Sandgren EP, Dege JL, et al. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990;62:447-456
6. Mohammed FF, Pennington CJ, Kassiri Z, et al. Metalloproteinase inhibitor TIMP-1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 2005;41:857-867
7. Sandgren EP, Palmiter RD, Heckel JL, et al. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991;66:245-256
8. Sandgren EP, Degen JL, Palmiter RD, et al. Replacement of diseased mouse liver by hepatic cell transplantation. Science 1994;263:1149-1152
9. Marongju F, Doratiotto S, Montisci S, et al. Liver repopulation and carcinogenesis: two sides of the same coin? Am J Pathol 2008;172:649-857
10. Rhim JA, Sandgren EP, Palmiter RD, et al. Complete reconstitution of mouse liver with xenogeneic hepatocytes. Proc Natl Acad Sci USA 1995;92:4942-4946
11. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007;213:286-300
12. Petersen J, Dandri M, Gupta S, et al. Liver repopulation with xenogeneic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma. Proc Natl Acad Sci USA 1998;95:310-315
13. Dandri M, Burda MR, Török E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 2001;33:981-988 (Pubitemid 32246649)
14. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001;7:927-933
15. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983;301:527-530
16. Perryman LE. Molecular pathology of severe combined immunodeficiency in mice, horses, and dogs. Vet Pathol 2004;41:95-100
17. Suemizu H, Hasegawa M, Kawai K, et al. Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun 2008;377:248-252
18. Kikutani H, Makino S. The murine autoimmune diabetes model: NOD and related strains. Adv Immunol 1992;51:285-322
19. Ohbo K, Suda T, Hashiyama M, et al. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 1996;87:956-967
20. Tateno C, Yoshizane Y, Saito N, et al. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004;165:901-912
21. Meuleman P, Libbrecht L, De Vos R, et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005;41:847-856
22. Kawada N, Kristensen DB, Asahina K, et al. Characterization of a stellate cell activation-associated protein (STAP) with peroxidase activity found in rat hepatic stellate cells. J Biol Chem 2001;276:25318-25323
23. Nishimura M, Yoshitsugu H, Yokoi T, et al. Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver. Xenobiotica 2005;35:877-890
24. Sarbah SA, Younossi ZM. Hepatitis C: an update on the silent epidemic. J Clin Gastroenterol 2000;30:125-143
25. Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antivir Res 2008;80:231-238
26. Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005;42:1046-1054
27. Gonzalez FJ, Yu AM. Cytochrome P450 and xenobiotic receptor humanized mice. Ann Rev Pharmacol Toxicol 2006;46:41-64
28. Hewitt NJ, Lecluyse EL, Ferguson SS. Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recommendations, and in vitro-in vivo correlations. Xenobiotica 2007;37:1196-1224
29. Graham MJ, Lake BG. Induction of drug metabolism: species differences and toxicological relevance. Toxicology 2008;254:184-191
30. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37
31. Yu AM, Idle JR, Gonzalez FJ. Polymorphic cytochrome P450 2D6: humanized mouse model and endogenous substrates. Drug Metab Rev 2004;36:243-277
32. Bogaards JJ, Bertrand M, Jackson P, et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000;30:1131-1152
33. Caldwell J. The current status of attempts to predict species differences in drug metabolism. Drug Metab Rev 1981;12:221-237
34. Masubuchi Y, Iwasa T, Hosokawa S, et al. Selective deficiency of debrisoquine 4-hydroxylase activity in mouse liver microsomes. J Pharmacol Exp Ther 1997;282:1435-1441
35. Katoh M, Sawada T, Soeno Y, et al. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J Pharm Sci 2007;96:428-437
36. Bowen WP, Carey JE, Miah A, et al. Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 2000;28:781-788
37. Katoh M, Matsui T, Nakajima M, et al. In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab Dispos 2005;33:754-763 (Pubitemid 40686628)
38. Toriyabe T, Nagata K, Takada T, et al. Unveiling a new essential cis element for the transactivation of the CYP3A4 gene by xenobiotics. Mol Pharmacol 2009;75:677-684
39. Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000;14:27-39
40. Cho IJ, Kim SG. Oltipraz inhibits 3-methylcholanthrene induction of CYP1A1 by CCAAT/enhancer-binding protein activation. J Biol Chem 2003;278:44103-44112
41. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-832
42. Katoh M, Matsui T, Okumura H, et al. Expression of human phase II enzymes in chimeric mice with humanized liver. Drug Metab Dispos 2005;33:1333-1340
43. Xie W, Yeuh M-F, Radominska-Pandya A, et al. Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor. Proc Natl Acad Sci USA 2003;100:4150-4155
44. Kodama S, Koike C, Negishi M, et al. Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol Cell Biol 2004;24:7931-7940
45. Zhang J, Huang W, Chua SS, et al. Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR. Science 2002;298:422-424
46. Okumura H, Katoh M, Sawad T, et al. Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol Sci 2007;97:533-538 (Pubitemid 47073867)
47. Ko H, Novak E, Peters GR, et al. Pharmacokinetics of single-dose cefmetazole following intramuscular administration of cefmetazole sodium to healthy male volunteers. Antimicrob Agents Chemother 1989;33:508-512
48. Murakawa T, Sakamoto H, Fukada S, et al. Pharmacokinetics of ceftizoxime in animals after parenteral dosing. Antimicrob Agents Chemother 1980;17:157-164 (Pubitemid 10128995)
49. Shoda J, Okada K, Inada Y, et al. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 2007;37:548-556
50. Masumoto N, Tateno C, Tachibana A, et al. GH enhances proliferation of human hepatocytes grafted into immunodeficient mice with damaged liver. J Endocrinol 2007;194:529-537